On August 31, 2023, Baudax Bio, Inc. entered into Amendment No. 7 to the Credit Agreement, by and among Baudax Bio, Baudax Bio N.A. LLC, Baudax Bio Limited and TeraImmune, LLC, the lenders party thereto (the Lenders") and Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent for the Lenders, which modifies that certain Credit Agreement, dated as of May 29, 2020. Pursuant to the amendment, the Lenders agreed to, among other things, defer certain loan amortization payments and waive the minimum liquidity financial maintenance covenant until December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0103 USD | -8.04% | -2.83% | -53.18% |
Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-53.18% | 540K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BXRXQ Stock
- News Baudax Bio, Inc.
- Baudax Bio, Inc. Enters into Amendment No. 7 to the Credit Agreement